Insight Molecular Diagnostics Inc. (IMDX) Financial Analysis & Valuation | Quarter Chart
Insight Molecular Diagnostics Inc. (IMDX)
IMDXPrice: $3.98
Fair Value: 🔒
🔒score
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and ... more
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes prop... more
Description
Shares
| Market Cap | $114.02M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Joshua Riggs |
| IPO Date | 2015-12-30 | CAGR | — |
| Employees | 46 | Website | imdxinc.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IMDX chart loading...
Fundamentals
Technicals
| Enterprise Value | $90.78M | P/E Ratio | -1.52 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 25.9 | P/B Ratio | -13.85 |
| P/CF Ratio | -5.79 | P/FCF Ratio | -4.77 |
| EPS | $-3.21 | EPS Growth 1Y | -36.08% |
| EPS Growth 3Y | -78.37% | EPS Growth 5Y | -72.32% |
| Revenue Growth 1Y | 520.87% | Gross Margin | 0.55% |
| Operating Margin | -13.93% | Profit Margin | -13.81% |
| ROE | 23.94% | ROA | -1.38% |
| ROCE | -1.69% | Current Ratio | 2.79 |
| Quick Ratio | 2.73 | Cash Ratio | 2.44 |
| Debt/Equity | -0.34 | Interest Coverage | -542.62 |
| Altman Z Score | -14.74 | Piotroski Score | 4 |